Comparative Pharmacology
Head-to-head clinical analysis: VITRASERT versus ZIRGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VITRASERT versus ZIRGAN.
VITRASERT vs ZIRGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitrasert (ganciclovir implant) releases ganciclovir, a nucleoside analog that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) after intracellular phosphorylation to ganciclovir triphosphate. This results in chain termination and viral DNA synthesis inhibition.
Ganciclovir is a synthetic guanine derivative that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) and by incorporating into viral DNA, causing chain termination. Ganciclovir is phosphorylated to ganciclovir triphosphate by viral thymidine kinase (UL97) in CMV-infected cells.
Intravitreal implant containing 0.59 mg fluocinolone acetonide; inserted into the vitreous cavity; releases drug over approximately 36 months; no systemic dosing.
Instill 1 drop (approximately 0.05 mL) into affected eye(s) 5 times daily (approximately every 3 hours while awake) until corneal ulcer heals, then reduce to 1 drop 3 times daily for 7 days.
None Documented
None Documented
Terminal half-life of 2.8 hours following intravitreal injection; sustained local levels for 2-3 weeks.
Terminal elimination half-life in patients with normal renal function is approximately 3-4 hours; in renal impairment, half-life may be prolonged up to 30 hours, requiring dose adjustment.
Primarily biliary/fecal (approximately 90%) with minimal renal excretion (<10% unchanged in urine).
Primarily renal excretion as unchanged drug via glomerular filtration and tubular secretion; >90% of a systemically absorbed dose is recovered unchanged in urine.
Category C
Category C
Antiviral
Antiviral